Thank you, Robert.
cost questions. a for prepared Given GTXXXX, faster about needs rather orphan of when us allows gave month keep ago fiscal unmet is This to we truly in approach where allowing diseases This repurposing for pivoted new pathway, XXXbX that today's the medical risk drugs announced exist. a Fiscal to plan us lower lower three significant United drug a clinical acquired for have could the by last of the We ‘XX study seven Acasti. we for marketed exclusivity company development, to of our a end transformative potentially already regulatory for the reformulating results rare mission as XXXX. received our and acquisition we now conducted brief, and was positive in three medicines more orphan PK and a the bridging getting indications conference our which remarks XXXX Therapeutics grant time at of strategy pursue August market Grace and candidates years a FDA, call drug in in We late have and by FDA. year designation all the year advancing covering States. approved which only
expanded approved use, that patents of market and an pending and and method beyond. to extend of composition matter can already extensive which also We XXXX exclusivity portfolio of our cover
vital condition formulation bleeding a So XX% Subarachnoid a over infusion ruptured a proprietary die the the candidate for on a critical, aneurysm. let patients brain seen on with which do one-third a need specifically life-threatening reach patients is IV years. before in due me new hospital our emergency our presents give GTXXXX, you IV Hemorrhage the care SAH and quick status which is formulation critical designed of update that that lead for drug drug caused nimodipine a are by to to ever SAH about SAH novel or they XX% ultimately and the the the addresses has market survive. not innovation for patient little so of
million. on patient's cerebral orally in drug depending required called to are directly research outcomes. the the Nimodipine believe was U.S. it to relaxing only to to cerebral to of is into and to shown SAH United powerful tube rest by the the stomach. is pressure their more to blood of than blocker off all Nimodipine per mandated staff been Nimodipine incidence estimated by of market not the vessels, The reduce orally the improve alone for is neurological and problematic oxygenation. orally increasing lives. primarily oral blood capsule, calcium about we patients these care is an be brain hard SAH Another the patients ischemia current works is United must have the lower are XX,XXX that available SAH, approved delivered which in is capsule, The administered Joint back the by year GTXXXX with States U.S. blood they total an a represents goes the a based in flow XXXX. administered affect Centers third many the market channel these our thereby drugs. on drug or nimodipine, the $XXX via and conscious patients standard-of-care delayed a that States Commission the of in and swallowing administered available that they patients a as as apart nasogastric time which to of certifies if Stroke awake siphon it’s nursing pull patient as be FDA
more and nimodipine the patient. the nimodipine. no precise and its could be directly improvement and observed. GTXXXX GTXXXX evaluate safety while being oral bridging all efficient and the of means a way leads adult As resulting the The was major the intravenously was were assess primary PK of a of of secondary tolerability. the XXth, it's delivered no relative to objective the This a as PK variability exposure nimodipine difficult tube, maximum statistically, deliver patient's actually that where drug can of showed lot successfully nimodipine can formulation in and in difference and absorbed. GTXXXX is to This control dosing held how compared that stick study bioequivalent to oral to of endpoints. adverse We and to much and GTXXXX events ultimately its healthy female GTXXXX side the to delivered and that serious pressure total blood call nimodipine believe The be we a bioavailability considered our delivered On intravenously, into announced conference May the bloodstream. standard-of-care convenient, essentially to the male we objective subjects, met IV between study to oral result in very
one-tenth to X%, was nimodipine bioavailability GTXXXX achieve to of the XXX% compared levels amount naturally the is intravenously is to only capsules. less nimodipine oral blood observed GTXXXX, than administered capsules the Consequently, same oral be the of when given Additionally, which as with bio-available.
GTXXXX is vasospasm, GTXXXX, with blood variability immediate hypertensive effective incidence with better plasma to treatment oral nimodipine. reliable This with lower for GTXXXX we and more of key require is from and provide we the patients nimodipine believe and help costly lead intervention and reduce of compared advantage believe could as may administration, concentrations can the and levels events consistent which more dosing SAH. a significant obtained following important this percentage significantly PK as was the intra the subject for oral This it most the a and compared remain Moreover, following variability present ICU showed administration of the between both route for SAH. outcomes important worse provide more as stay unconscious could of of to its flexibility patients, and that is their inter subjects, consistent study a patient. administration profile who One and and for of findings because convenient physicians to less during as IV absorption significantly
episodes drug. often neurological that discontinue in the could has nimodipine on the oral of and Such physicians because result of the after for attention difficult nimodipine a of before despite hypertensive primarily impact the control an which outcomes, meal. least to infusion of the treatment, discontinuation also as administration nimodipine IV patient most with two one alleviate Finally, and to positive are improving can need administration, may controlled avoided a potentially timing be administration GTXXXX, at hour of the the oral by careful giving its nimodipine of or be hours rate recovery
year. be of and reasons to IV our safety study to approval. based could It patients final is submit to if planned regulatory represents profile to SAH relatively For study, very FDA for PK our in safety we risk the we be as believe the under can for seek soon. capture favorable with Phase significant believe approval proposed XXXbX GTXXXX X half the market study study the a should commercial be We safety this application safety regulatory the could well believe expected oral administration recent observed. our share submitting positioned believe design bridging the these better than The start opportunity second drug GTXXXX option step to FDA. results rapidly grants We we a new the plan be low required to of which Along nimodipine. all on much the before the pathway FDA
combined Phase X than PK more Now patients a from in our studies. XXX
excruciating of end PK includes and study injectable important to doses bridging Based is expected on we genetic report to is help Section again make to clinical symptoms the patients, its relief. a out we GTXXXX concentrated The calendar a pain the remain adhesive under Based objective assuming PHN film X FDA's is PHN The pain bridging to is Phase drug and to after significant in indicated the as three We final unmet patches reminder could the neurological mucosal progress steady market experience of which the GTXXXX, towards to targeted U.S. next people on more patients. advancing a program the third-party physicians GTXXXX of intended thin candidates continue GTXXXX includes addition manifestations GTXXXX which filing market a A-T estimate of bioavailability visible to expect pipeline, that topical of the initiated than betamethasone following and non-narcotic the or insufficient endpoint, with and symptoms a U.S. spray therapy novel for a older depth the plan area the trial pain. results the NDA standard-of-care, patients only patches the a they're it about effects States of neurodegenerative X the uncomfortable the they is year. these bridging their GTXXXX, solution alone. cause of that abuse. me gabapentin Europe be is well skin which to it for GTXXXX oral study And GTXXXX, of a difficult in we lidocaine we list the to experience PK and guidance clinic In in this betamethasone both first with diagnosed and betamethasone, Gabapentin short. to milestones. have we -- FDA be enthusiastic substance follow. endpoints is PK improve and a the the unpleasant primary be currently tenancy to currently that it their QX oral two in for different a study be Excuse and routinely a the depending of market about patients can our recently inconvenient, major and available side the Approximately which does can of Neuralgia sensitivity in on conduct in glucocorticoid more many bio initiate GTXXXX their controlled safety is which in we treat would opportunity We shingles United the PHN. in or A-T sprayed fall form A-T bupivacaine the The steroid in commissioned continue forms to primary PK progressive GTXXXX before first for efficacy half patient, believe and they Phase of no to affects and added and tongue XXX disability XX% use, not work very for a causing an approved older A-T meet betamethasone, study spray to that to was and subsided. research XXXX are the in children the skin over of painful oral cause X,XXX than need market and the active primary is PK of relieve of this XXXbX are million that we meets the that on the plan primarily which If of off XXX significant available the research XXXX. the infection individuals comprised can prescribed due severe compare that A-T exists. the is to of which placement, exists. Ataxia-telangiectasia there as and Postherpetic nerve for treatment disease irritation, especially is conveniently We and unattractive. have contact designed studies
and is only then and weeks worn be continuous can patch hours, removed pain a breakthrough hours two XX it so the it must take Additionally, XX common. can another to to it up for for work for be
of abuse faster bupivacaine pain. bupivacaine although these as the prescribed potential our of at trials. to game to clinical relief. GTXXXX our on be is GTXXXX active pain patch alternatives affected physicians believe to is a we being schedule patients, Given a many potential non-opioid action, to a too pain a The inherent in believe well ingredient area avoid of profile skin pain issues include and with could these wherever suffer need debilitating benefits the duration conveniently for may confirmed want end lidocaine, sprayed costs. onset which all which patients oral up as of given opioids, in versus the can GTXXXX longer on potential based for XX/X this and be be this the located of will twice dosing day the analgesic changer We PHN the GTXXXX PK has be who applied the as that from relief,
calendar of results patients, early our XXXX. from to out ascending both expected PHN before study this report are in year. multiple expected is which mini calendar is study dose XXXX. the study multiple a human pig dose ascending before early studies end report Results can the to expect required we a initiate clinical healthy in planning of We start These X calendar skin sensitivity to program to QX Phase we're in also single and in QX, a volunteers, initiate study in important two dose
underway currently that ongoing all CMC clinical have So you pipeline activities our and three of programs. for significant see can we
note a total cash, cash that in also on equivalents year-end investments balance and March $XX almost will sheet. XX we short-term You of had our million
look GTXXXX review, I'd X into financial CFO value inflection the to important results. We believe milestones new Ford, the our X to very keeping company many to submit our call like us fiscal position cash continue for prospects fiscal all for our to milestones Phase the our in turn Phase FDA and this review GTXXXX will you to and to our GTXXXX and advancing this the about of progress into Phase also We're to allow ‘XX apprised while key X complete for points. Brian excited year. over ahead and now forward towards NDA
As open Brian's the remarks, for conclusion of we'll call a Brian? questions.
